Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma

Attila Nakeeb, Henry A. Pitt

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background. Hilar cholangiocarcinoma is a rare tumour which is best managed by an aggressive surgical approach. The role of adjuvant or neoadjuvant radiation therapy, chemotherapy or chemoradiation remains controversial, as no prospective randomized studies have been performed. Methods. This review summarizes the recent literature regarding the role of radiation, chemotherapy and chemoradiation in hilar cholangiocarcinoma. The results of a biliary cancer questionnaire regarding current treatment strategies are also reported. Results. A number of retrospective studies have shown that patients treated with adjuvant radiation therapy have prolonged survival compared with untreated patients. However, most of these reports did not control for tumour stage or performance status. A carefully controlled trial from the Johns Hopkins Hospital did not demonstrate any benefit for adjuvant radiation therapy. A number of phase II trials of chemotherapy have demonstrated modest response rates (20-40%). The best responses have been reported with 5-fluorouracil (5-FU) in combination with interferon-alpha or with leucovorin and mitomycin C. Recent non-randomized reports of chemoradiation with 5-FU with or without gemcitabine as the radiosensitizer suggest, but do not prove, improved survival. Adjuvant chemoradiation is currently being employed at specialized centres most often in the Americas (71%) and the Asia/Pacific region (55%) and to a lesser degree in Europe (29%). Discussion. The only chance for long-term survival in patients with hilar cholangiocarcinoma is complete resection with negative margins. Neither radiation therapy nor chemotherapy alone has been proven to prolong survival in completely or partially resected patients or in unresected patients. Recent uncontrolled data suggest that chemoradiation may improve survival in resected and locally unresectable patients. However, prospective, randomized multicentre trials need to be performed to confirm efficacy.

Original languageEnglish
Pages (from-to)278-282
Number of pages5
JournalHPB
Volume7
Issue number4
DOIs
StatePublished - 2005

Fingerprint

Klatskin Tumor
Radiotherapy
Drug Therapy
Survival
gemcitabine
Fluorouracil
Biliary Tract Neoplasms
Neoadjuvant Therapy
Leucovorin
Mitomycin
Interferon-alpha
Multicenter Studies
Neoplasms
Retrospective Studies
Prospective Studies
Radiation

Keywords

  • Chemoradiation
  • Chemotherapy
  • Cholangiocarcinoma
  • Radiation therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. / Nakeeb, Attila; Pitt, Henry A.

In: HPB, Vol. 7, No. 4, 2005, p. 278-282.

Research output: Contribution to journalArticle

@article{100dbe3208584c9f9a6dd22df4f3e69a,
title = "Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma",
abstract = "Background. Hilar cholangiocarcinoma is a rare tumour which is best managed by an aggressive surgical approach. The role of adjuvant or neoadjuvant radiation therapy, chemotherapy or chemoradiation remains controversial, as no prospective randomized studies have been performed. Methods. This review summarizes the recent literature regarding the role of radiation, chemotherapy and chemoradiation in hilar cholangiocarcinoma. The results of a biliary cancer questionnaire regarding current treatment strategies are also reported. Results. A number of retrospective studies have shown that patients treated with adjuvant radiation therapy have prolonged survival compared with untreated patients. However, most of these reports did not control for tumour stage or performance status. A carefully controlled trial from the Johns Hopkins Hospital did not demonstrate any benefit for adjuvant radiation therapy. A number of phase II trials of chemotherapy have demonstrated modest response rates (20-40{\%}). The best responses have been reported with 5-fluorouracil (5-FU) in combination with interferon-alpha or with leucovorin and mitomycin C. Recent non-randomized reports of chemoradiation with 5-FU with or without gemcitabine as the radiosensitizer suggest, but do not prove, improved survival. Adjuvant chemoradiation is currently being employed at specialized centres most often in the Americas (71{\%}) and the Asia/Pacific region (55{\%}) and to a lesser degree in Europe (29{\%}). Discussion. The only chance for long-term survival in patients with hilar cholangiocarcinoma is complete resection with negative margins. Neither radiation therapy nor chemotherapy alone has been proven to prolong survival in completely or partially resected patients or in unresected patients. Recent uncontrolled data suggest that chemoradiation may improve survival in resected and locally unresectable patients. However, prospective, randomized multicentre trials need to be performed to confirm efficacy.",
keywords = "Chemoradiation, Chemotherapy, Cholangiocarcinoma, Radiation therapy",
author = "Attila Nakeeb and Pitt, {Henry A.}",
year = "2005",
doi = "10.1080/13651820500373028",
language = "English",
volume = "7",
pages = "278--282",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma

AU - Nakeeb, Attila

AU - Pitt, Henry A.

PY - 2005

Y1 - 2005

N2 - Background. Hilar cholangiocarcinoma is a rare tumour which is best managed by an aggressive surgical approach. The role of adjuvant or neoadjuvant radiation therapy, chemotherapy or chemoradiation remains controversial, as no prospective randomized studies have been performed. Methods. This review summarizes the recent literature regarding the role of radiation, chemotherapy and chemoradiation in hilar cholangiocarcinoma. The results of a biliary cancer questionnaire regarding current treatment strategies are also reported. Results. A number of retrospective studies have shown that patients treated with adjuvant radiation therapy have prolonged survival compared with untreated patients. However, most of these reports did not control for tumour stage or performance status. A carefully controlled trial from the Johns Hopkins Hospital did not demonstrate any benefit for adjuvant radiation therapy. A number of phase II trials of chemotherapy have demonstrated modest response rates (20-40%). The best responses have been reported with 5-fluorouracil (5-FU) in combination with interferon-alpha or with leucovorin and mitomycin C. Recent non-randomized reports of chemoradiation with 5-FU with or without gemcitabine as the radiosensitizer suggest, but do not prove, improved survival. Adjuvant chemoradiation is currently being employed at specialized centres most often in the Americas (71%) and the Asia/Pacific region (55%) and to a lesser degree in Europe (29%). Discussion. The only chance for long-term survival in patients with hilar cholangiocarcinoma is complete resection with negative margins. Neither radiation therapy nor chemotherapy alone has been proven to prolong survival in completely or partially resected patients or in unresected patients. Recent uncontrolled data suggest that chemoradiation may improve survival in resected and locally unresectable patients. However, prospective, randomized multicentre trials need to be performed to confirm efficacy.

AB - Background. Hilar cholangiocarcinoma is a rare tumour which is best managed by an aggressive surgical approach. The role of adjuvant or neoadjuvant radiation therapy, chemotherapy or chemoradiation remains controversial, as no prospective randomized studies have been performed. Methods. This review summarizes the recent literature regarding the role of radiation, chemotherapy and chemoradiation in hilar cholangiocarcinoma. The results of a biliary cancer questionnaire regarding current treatment strategies are also reported. Results. A number of retrospective studies have shown that patients treated with adjuvant radiation therapy have prolonged survival compared with untreated patients. However, most of these reports did not control for tumour stage or performance status. A carefully controlled trial from the Johns Hopkins Hospital did not demonstrate any benefit for adjuvant radiation therapy. A number of phase II trials of chemotherapy have demonstrated modest response rates (20-40%). The best responses have been reported with 5-fluorouracil (5-FU) in combination with interferon-alpha or with leucovorin and mitomycin C. Recent non-randomized reports of chemoradiation with 5-FU with or without gemcitabine as the radiosensitizer suggest, but do not prove, improved survival. Adjuvant chemoradiation is currently being employed at specialized centres most often in the Americas (71%) and the Asia/Pacific region (55%) and to a lesser degree in Europe (29%). Discussion. The only chance for long-term survival in patients with hilar cholangiocarcinoma is complete resection with negative margins. Neither radiation therapy nor chemotherapy alone has been proven to prolong survival in completely or partially resected patients or in unresected patients. Recent uncontrolled data suggest that chemoradiation may improve survival in resected and locally unresectable patients. However, prospective, randomized multicentre trials need to be performed to confirm efficacy.

KW - Chemoradiation

KW - Chemotherapy

KW - Cholangiocarcinoma

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=33745089310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745089310&partnerID=8YFLogxK

U2 - 10.1080/13651820500373028

DO - 10.1080/13651820500373028

M3 - Article

C2 - 18333207

AN - SCOPUS:33745089310

VL - 7

SP - 278

EP - 282

JO - HPB

JF - HPB

SN - 1365-182X

IS - 4

ER -